Key Highlights
- CVS delivered adjusted earnings per share of $2.57, crushing Wall Street’s $2.18 projection for the fifth quarter running
- Quarterly revenue reached $100.4 billion, significantly exceeding the $95 billion consensus estimate
- Aetna’s medical benefit ratio dropped to 84.6% from 87.3% in the prior-year period
- 2026 adjusted EPS guidance increased to $7.30–$7.50 range from previous $7.00–$7.20 outlook
- Shares rallied 4.9% in early trading as investors embraced the upbeat results
CVS Health shares surged 4.9% during Wednesday’s premarket session following the healthcare giant’s impressive first-quarter performance and enhanced annual forecast.
The company reported adjusted profit of $2.57 per share, handily surpassing the $2.18 Wall Street consensus. Quarterly sales of $100.4 billion likewise exceeded expectations, topping the $95 billion analysts had projected.
This represents the fifth consecutive quarter CVS has beaten earnings forecasts. Management has maintained conservative guidance throughout its ongoing transformation efforts following challenges experienced in 2024.
CVS elevated its 2026 full-year adjusted earnings per share projection to $7.30 to $7.50, compared with the prior range of $7.00 to $7.20. The company simultaneously increased its operating cash flow target to no less than $9.5 billion from at least $9 billion previously.
Prior to Wednesday’s announcement, the stock had advanced only 1.7% in 2025, underperforming the S&P 500’s 6% gain during the same timeframe.
Aetna Insurance Unit Shows Strong Cost Control
The most impressive metric was Aetna’s medical benefit ratio, which registered 84.6%—substantially below analyst expectations of 87.58% and down from 87.3% in the comparable quarter last year.
This ratio indicates what percentage of premium income goes toward paying for medical services. Lower figures translate to higher profitability. CFO Brian Newman attributed the enhancement to superior forecasting capabilities and disciplined expense management.
Both UnitedHealth and Humana similarly exceeded projections on this measure during the first quarter, suggesting widespread operational improvements among Medicare Advantage providers.
Federal authorities announced in April that 2027 reimbursement rates for Medicare Advantage plans would increase by an average of 2.48%. Newman noted this bump remains insufficient to cover anticipated cost escalations next year, potentially requiring CVS to modify pricing structures or benefit offerings.
Caremark Grows While Retail Pharmacy Faces Headwinds
The health services division, home to the Caremark pharmacy benefit manager, saw revenue climb 11% to $48.2 billion. The segment generated $1.34 billion in operating income, matching analyst projections.
According to Newman, a more favorable pharmaceutical mix contributed to Caremark’s solid performance. Leerink analyst Michael Cherny had previously identified the $1.3 billion adjusted operating income threshold as critical for rebuilding market confidence in the PBM business.
Pharmacy benefit managers continue facing scrutiny from legislators and regulatory bodies regarding drug pricing mechanisms. CVS is working toward an FTC settlement concerning accusations its PBM raised insulin costs, claims the company disputes.
The retailer is also challenging Tennessee legislation that would prohibit PBMs from operating pharmacies within state borders. The measure has cleared the state legislature and now awaits the governor’s decision.
CVS’s retail pharmacy division recorded 5% revenue growth in 2025 following its acquisition of Rite Aid locations, which brought 9 million new customers. However, the unit’s operating income declined 8.8% year-over-year in the first quarter.
Management pointed to regulatory modifications affecting certain medication prices, reduced cold and flu season activity, and weather-related disruptions—including snow-forced store closures—as contributing factors to the pharmacy segment’s profitability challenges.
